EMA work programme predicts steady increase in new drug applications

EMA logoIn its 2013 work programme, published today, the European Medicines Agency (EMA) forecasts that the total number of initial applications for evaluation of human medicines will remain stable. However, the agency predicts a continuing shift in the balance of applications, with the proportion of applications relating to generics declining, while applications new medicinal products and new orphan medicinal products both increasing. It is expected that these two categories combined will make up almost 75% of the agency’s new applications in 2013.

This site uses Akismet to reduce spam. Learn how your comment data is processed.